Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxIncreased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis AntigenTesting the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of TuberculosisAntibodies and tuberculosisAdjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationDissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional modelAccelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.Novel vaccination approaches to prevent tuberculosis in childrenSmallpox and Dracunculiasis: The Scientific Value of Infectious Diseases That Have Been Eradicated or Targeted for Eradication. Is Schistosomiasis Next?Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesCardio-Thoracic Ratio Is Stable, Reproducible and Has Potential as a Screening Tool for HIV-1 Related Cardiac Disorders in Resource Poor Settings.QuantiFERON conversion following tuberculin administration is common in HIV infection and relates to baseline response.Tuberculosis vaccine development: Shifting focus amid increasing development challenges.Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85AESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivoCurrent status of new tuberculosis vaccine in children.A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.Characterization of Mycobacterium tuberculosis-Specific Cells Using MHC Class II Tetramers Reveals Phenotypic Differences Related to HIV Infection and Tuberculosis Disease.A review of clinical models for the evaluation of human TB vaccines.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Towards new TB vaccines: What are the challenges?Human biomarkers: can they help us to develop a new tuberculosis vaccine?A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.Design of tuberculosis vaccine trials under financial constraints.From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology.Effect of HIV on the Frequency and Number of Mycobacterium tuberculosis-Specific CD4+ T Cells in Blood and Airways During Latent M. tuberculosis Infection.Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains.Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis
P2860
Q24273364-800B29A0-38C8-400B-90B7-CE2C057F42FEQ27302995-33E18F07-718E-42FB-8E8A-17C7542C5B41Q27327288-68AD63E9-B194-437E-BA90-050A6248579BQ28067735-12915AA5-D911-4C9C-B384-9CEE31FE98FBQ28074536-FA7E855C-82EB-46AA-B280-731520B8FAE3Q28468572-1094C2EA-332E-4AF7-A5A6-713F334C0CA0Q30403003-E7C996D9-32B4-4B2E-A910-B07E0A7B6DCEQ33637297-6F2A70C0-CE6E-4AFC-A54A-60BF7ED90907Q33801426-A27B7FBA-64B9-489E-AD25-B8E7F76068B6Q35887900-70C6D52E-364A-44FE-8861-02DC8398ACCDQ35928588-2C5EC42B-AB58-4FD5-9537-C286416B1DD3Q36152663-E3E1B383-1C8B-4F50-8E5E-3110C195279CQ36157985-6A311DB6-E23B-49EE-9E68-4C58F48EF4D8Q36256304-C8635A52-1DC8-43AE-9A0C-5CF805EF5F9EQ36369598-444E9A33-9816-4151-9BFF-9AF08EDDAD3BQ36951826-B005A289-4796-4D5E-903D-CCDAB62835FCQ37130796-FFF06436-E55D-4EDF-85B9-1AE6D0AC3695Q37204894-291B5377-BBFA-4612-BD97-B6651E11D0D7Q37737549-DB3C7A69-C585-471F-8FD2-DC2EE9EC9F77Q38631641-AB12BFD1-6977-48DF-BE22-BBF39459D1BFQ38711772-723D469E-D736-4EAC-A272-5886EF6AA530Q38724073-724ECAA5-92EE-4FC2-A55E-5EEC87AB2934Q38767468-7F8BFF3A-F170-4DF1-8482-BC823576D271Q38839838-BD2630F0-600F-4D5D-A36C-FB5B635D6B27Q40107672-58F91F56-E456-40BA-AC06-191DBA5810FBQ40171033-05D32BCB-0C87-49CA-9B7E-1FA67CB04AFEQ40190981-303B02FB-0CBC-44E1-8492-25DA227E5EF2Q40411515-41CBE7D0-5ADC-4E23-9B4B-2A79333B09CEQ40714734-ACC80885-BE42-44D9-9F88-40CABB20546BQ40914004-5CD39C2F-9A9E-47A1-B759-5F8BA9E8C87BQ46729892-907AD484-69B4-44C8-8810-55B7E52D966BQ47613899-92C4D341-3621-48A5-BCD3-364A4974FE2EQ47828181-216D52B6-3431-43D9-82A6-B6C906A27F77Q56976379-F3B4E080-3841-46B9-9F2F-494F7612DD99
P2860
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@ast
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@en
type
label
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@ast
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@en
prefLabel
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@ast
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@en
P2093
P2860
P50
P921
P1476
Safety, immunogenicity, and ef ...... ebo-controlled, phase 2 trial.
@en
P2093
Aminata Thiam
Bernard S Landry
Birahim Pierre Ndiaye
Ibrahima Ndiaye
Iman Satti
MVA85A 030 trial investigators
Makhtar Camara
Marta Romano
Martin Ota
Michael Raine
P2860
P304
P356
10.1016/S2213-2600(15)00037-5
P50
P577
2015-02-26T00:00:00Z